Japan · Delayed Price · Currency is JPY Fuji Pharma Statistics
Total Valuation
Fuji Pharma has a market cap or net worth of JPY 61.09 billion. The enterprise value is 79.83 billion.
| Market Cap | 61.09B |
| Enterprise Value | 79.83B |
Important Dates
The last earnings date was Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | Sep 29, 2026 |
Share Statistics
Fuji Pharma has 26.12 million shares outstanding. The number of shares has increased by 1.15% in one year.
| Current Share Class | 26.12M |
| Shares Outstanding | 26.12M |
| Shares Change (YoY) | +1.15% |
| Shares Change (QoQ) | +2.84% |
| Owned by Insiders (%) | 40.03% |
| Owned by Institutions (%) | 14.81% |
| Float | 12.56M |
Valuation Ratios
The trailing PE ratio is 23.74 and the forward PE ratio is 14.47.
| PE Ratio | 23.74 |
| Forward PE | 14.47 |
| PS Ratio | 1.07 |
| PB Ratio | 1.19 |
| P/TBV Ratio | 1.62 |
| P/FCF Ratio | 11.09 |
| P/OCF Ratio | 7.90 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.18, with an EV/FCF ratio of 14.49.
| EV / Earnings | 32.90 |
| EV / Sales | 1.39 |
| EV / EBITDA | 7.18 |
| EV / EBIT | 11.27 |
| EV / FCF | 14.49 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.58.
| Current Ratio | 1.68 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.66 |
| Debt / FCF | 5.38 |
| Interest Coverage | 18.69 |
Financial Efficiency
Return on equity (ROE) is 5.00% and return on invested capital (ROIC) is 8.07%.
| Return on Equity (ROE) | 5.00% |
| Return on Assets (ROA) | 4.64% |
| Return on Invested Capital (ROIC) | 8.07% |
| Return on Capital Employed (ROCE) | 10.79% |
| Weighted Average Cost of Capital (WACC) | 4.34% |
| Revenue Per Employee | 32.56M |
| Profits Per Employee | 1.38M |
| Employee Count | 1,760 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.45 |
Taxes
In the past 12 months, Fuji Pharma has paid 507.00 million in taxes.
| Income Tax | 507.00M |
| Effective Tax Rate | 17.29% |
Stock Price Statistics
The stock price has increased by +81.04% in the last 52 weeks. The beta is 0.31, so Fuji Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +81.04% |
| 50-Day Moving Average | 2,297.90 |
| 200-Day Moving Average | 1,900.91 |
| Relative Strength Index (RSI) | 58.86 |
| Average Volume (20 Days) | 168,375 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Fuji Pharma had revenue of JPY 57.30 billion and earned 2.43 billion in profits. Earnings per share was 98.53.
| Revenue | 57.30B |
| Gross Profit | 23.21B |
| Operating Income | 7.08B |
| Pretax Income | 2.93B |
| Net Income | 2.43B |
| EBITDA | 11.11B |
| EBIT | 7.08B |
| Earnings Per Share (EPS) | 98.53 |
Balance Sheet
The company has 10.89 billion in cash and 29.62 billion in debt, with a net cash position of -18.73 billion or -717.04 per share.
| Cash & Cash Equivalents | 10.89B |
| Total Debt | 29.62B |
| Net Cash | -18.73B |
| Net Cash Per Share | -717.04 |
| Equity (Book Value) | 51.36B |
| Book Value Per Share | 2,041.93 |
| Working Capital | 22.02B |
Cash Flow
In the last 12 months, operating cash flow was 7.73 billion and capital expenditures -2.22 billion, giving a free cash flow of 5.51 billion.
| Operating Cash Flow | 7.73B |
| Capital Expenditures | -2.22B |
| Depreciation & Amortization | 4.03B |
| Net Borrowing | -2.18B |
| Free Cash Flow | 5.51B |
| FCF Per Share | 210.87 |
Margins
Gross margin is 40.50%, with operating and profit margins of 12.36% and 4.23%.
| Gross Margin | 40.50% |
| Operating Margin | 12.36% |
| Pretax Margin | 5.12% |
| Profit Margin | 4.23% |
| EBITDA Margin | 19.40% |
| EBIT Margin | 12.36% |
| FCF Margin | 9.61% |
Dividends & Yields
This stock pays an annual dividend of 47.00, which amounts to a dividend yield of 2.01%.
| Dividend Per Share | 47.00 |
| Dividend Yield | 2.01% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 45.88% |
| Buyback Yield | -1.15% |
| Shareholder Yield | 0.86% |
| Earnings Yield | 3.97% |
| FCF Yield | 9.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Fuji Pharma has an Altman Z-Score of 2.13 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.13 |
| Piotroski F-Score | 8 |